IgG4-Related and Inflammatory Diseases
IgG4-Related and Inflammatory Diseases is a research topic within Rheumatology. Science Explorer counts 14k research works in it since 1950. 10.1% of them reached the world's top 10% most cited for their field and year.
This cluster of papers focuses on the diagnosis and management of IgG4-related disease, including autoimmune pancreatitis, inflammatory myofibroblastic tumor, and sclerosing cholangitis. It discusses the diagnostic criteria, pathological features, clinical profiles, and therapeutic approaches such as rituximab therapy for this systemic disease.
- IgG4-Related Disease
- Autoimmune Pancreatitis
- Inflammatory Myofibroblastic Tumor
- Sclerosing Cholangitis
- Diagnostic Criteria
- Immunoglobulin G4
- Pathological Features
- Rituximab Therapy
- Clinical Profile
- Systemic Disease
- Research works
- 14k fractional, since 1950
- In the world top 10%
- 1.4k per year above
- Top-10% rate
- 10.1% share of its works in the world top 10%
- Growth, 2018-21 → 2022-25
- +16% the tick is no change
- Largest producer
United States
26% of the 10 largest, 2022-now
This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.
Which countries lead IgG4-Related and Inflammatory Diseases research?
By volume, the United States and China publish the most (669 and 617 works in 2022-now).
By volume, 2022-now
- 1
United States 669 works
- 2
China 617 works
- 3
Japan 401 works
- 4
India 245 works
- 5
Spain 122 works
- 6
Italy 112 works
- 7
United Kingdom 100 works
- 8
Türkiye 96 works
- 9
Germany 93 works
- 10
France 92 works
How concentrated that is
The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.
Shares of the rows listed above, not of the whole node.
Which institutions lead IgG4-Related and Inflammatory Diseases research?
By volume in 2022-now, Harvard University publishes the most IgG4-Related and Inflammatory Diseases research, followed by Capital Medical University and Mayo Clinic.
By volume, 2022-now
- 1
Harvard University
United States 37 works
- 2
Capital Medical University
China 36 works
- 3
Mayo Clinic
United States 36 works
- 4
All India Institute of Medical Sciences
India 27 works
- 5
Peking University
China 25 works
- 6
Sichuan University
China 23 works
- 7
Chinese Academy of Medical Sciences & Peking Union Medical College
China 22 works
- 8
Tsinghua University
China 20 works
- 9
Sun Yat-sen University
China 18 works
- 10
Zhejiang University
China 17 works
Who are the leading researchers in IgG4-Related and Inflammatory Diseases?
The most-cited researchers publishing on IgG4-Related and Inflammatory Diseases include Giuseppe Remuzzi, Kai You Wang and Alberto Arduan Ortiz.
- 1
Giuseppe Remuzzi
Italy 328k citations
- 2
Kai You Wang
China 224k citations
- 3
Alberto Arduan Ortiz
Spain 219k citations
- 4
Marc Ladanyi
United States 217k citations
- 5
Ralph H. Hruban
United States 209k citations
Ranked by citations received across their whole record, among researchers with at least three works on this topic.
Where is IgG4-Related and Inflammatory Diseases research done?
The largest centres of IgG4-Related and Inflammatory Diseases research in 2022-now are Beijing (China), Tokyo (Japan), Shanghai (China) and New Delhi (India).
Where is the best place to study IgG4-Related and Inflammatory Diseases?
Among universities, judged by research, Harvard University, Capital Medical University and Chinese Academy of Medical Sciences & Peking Union Medical College score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.
One dot per university in the first ten of the table below, at the default weights. The upper left is the interesting corner: small places doing unusually strong work.
Universities only. The score blends excellence (40%), size (30%), specialisation (10%), growth (10%), international reach (10%), 2022-now; growth compares 2018-21 with 2022-25 and counts up to +20%, since a jump from a small base is mostly noise.
Every institution in IgG4-Related and Inflammatory Diseases, country by countryIs IgG4-Related and Inflammatory Diseases research growing?
Output in 2022-2025 was 16% higher than in 2018-2021, peaking in 2025. The fastest-growing topics are IgG4-Related and Inflammatory Diseases.
The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.
Its share of all research
Growing output can still be a shrinking share: all of science grows. This is IgG4-Related and Inflammatory Diseases as a percentage of every work published that year, 0.012% in 2024.
Fractional works of IgG4-Related and Inflammatory Diseases over all fractional works that year. How the balance of science has shifted.
How much of it reaches the world top 10%
Year by year.
Of each year's works in it, the share that reached the world's 10% most cited for their field and year. A field is the world for its own topics, so there is no other line to hold it against.
Which topics inside it are moving
Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.
Discussion
Ask a question or share a note about IgG4-Related and Inflammatory Diseases. Posts are plain text and can be reported.